Why AI Pilots Stall in Life Sciences: The Missing Expertise Behind Scale

AI is creating new opportunities across drug discovery, clinical development, laboratory operations, and regulatory affairs, but moving from promising pilots to reliable, scalable capabilities remains a challenge. Success requires more than technology. Life sciences organizations need scientific, data, and regulatory expertise to ensure AI outputs are trustworthy, traceable, and appropriate for their intended use.

The FDA and EMA’s January 2026 guiding principles for good AI practice in drug development emphasize multidisciplinary expertise, data governance, risk-based evaluation, and lifecycle management. Understanding these principles, addressing expertise gaps, and establishing effective collaboration between people, AI, and specialized experts are essential to scaling AI responsibly across life sciences organizations.

Read More